|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,166,197
Executive Summary
U.S. Patent 6,166,197 (hereafter "the '197 patent") was granted on December 26, 2000, to Novartis AG. It covers key aspects of a class of dihydroorotate dehydrogenase (DHODH) inhibitors, primarily focusing on compounds with immunomodulatory and antiproliferative properties. This patent has played a pivotal role in the development of drugs such as leflunomide, used in autoimmune diseases and certain cancers. Its broad claims have significantly shaped the landscape of DHODH inhibitor patents, spurring numerous filings and litigations.
This report provides a comprehensive analysis of the '197 patent's scope and claims, contextualizing its position within the patent landscape for DHODH inhibitors and related therapeutics. It aims to assist professionals in understanding patent protections, potential infringement risks, and opportunities for innovation.
1. Summary of the '197 Patent
Filing Date: August 1, 1997
Issue Date: December 26, 2000
Applicants: Novartis AG
Main Focus: Novel heterocyclic compounds with DHODH inhibitory activity, pharmaceutical compositions, and methods of use in autoimmune diseases, transplant rejection, and cancers.
Key Aspects:
- Subject Matter: Heterocyclic compounds characterized by specific chemical structures capable of inhibiting DHODH.
- Therapeutic Applications: Treatment of autoimmune diseases (e.g., rheumatoid arthritis, psoriasis), transplantation rejection, and certain proliferative disorders.
- Diversity of Compounds: The patent claims a broad class of structures, including various substitutions on the heterocyclic core.
2. Scope and Claims Analysis
2.1. Overview of Patent Claims
The '197 patent contains multiple claims, broadly divided into independent and dependent claims.
| Type of Claims |
Number |
Scope |
Purpose |
| Independent Claims |
6 |
Cover fundamental heterocyclic compounds with specific substitutions; methods of treating diseases using these compounds. |
Establish core rights for the compounds and their use. |
| Dependent Claims |
34 |
Narrower claims, specifying particular substitutions, salts, formulations, or uses. |
Enhance patent robustness and provide fallback positions. |
2.2. Core Elements of the Claims
| Claim Element |
Details |
Implication |
| Heterocyclic Core |
Pyrimidine, pyrimidinone, or pyrimidinedione structures. |
Focus on specific heterocycles known for DHODH inhibition. |
| Substituents |
Variability at key positions; e.g., alkyl, aryl groups, or heteroatoms. |
Supports broad coverage across derivatives. |
| Pharmacologically Active Moiety |
Structures that inhibit DHODH enzyme activity. |
Ensures claims pertain to therapeutic compounds. |
| Method of Use |
Treating autoimmune or proliferative diseases. |
Protects therapeutic applications. |
2.3. Notable Claims Extract
| Claim Number |
Key Elements |
Scope |
| Claim 1 |
A heterocyclic compound of formula (I) comprising specific substitutions suitable for DHODH inhibition. |
Broad chemical class claim. |
| Claim 2 |
Method of inhibiting DHODH activity using the compound of claim 1. |
Method claim, extending rights to methods of therapy. |
| Claim 3–6 |
Specific compounds with particular substituents, salts, and formulations. |
Narrower claims for enforceability against specific compounds. |
Note: The patent’s claims are intentionally broad, aiming to cover a wide chemical space of DHODH inhibitors with potential medicinal applications.
3. Patent Landscape Context
3.1. Related Patents and Family Members
The '197 patent is part of a patent family including:
| Patent Number |
Jurisdiction |
Status |
Main Focus |
| EP 0866300 B1 |
Europe |
Granted |
Similar compounds, extending the claims to Europe. |
| WO 97/36109 |
PCT Application |
Published |
International phase, detailed synthesis routes. |
| US 6,166,197 |
US |
Granted |
Core patent as described. |
3.2. Competitor Claims & Inventive Barriers
- Several companies, including Sanofi-Aventis, Johnson & Johnson, and Bristol-Myers Squibb, have filed patents on derivatives and methods targeting DHODH.
- The scope of the '197 patent has been cited as a barrier for biosimilar and generic versions of leflunomide in certain markets.
- Noteworthy is the patent's potential to block or require licensing for newer DHODH inhibitors.
3.3. Patent Litigation & Legal Status
While there has been limited litigation directly affecting the '197 patent, its citations in patent challenges and freedom-to-operate analyses are significant:
- Leflunomide patent extensions and competitors' claims often reference the '197 patent.
- Regulatory exclusivity for leflunomide expired in many jurisdictions, but patent rights remain influential.
- The broad claims have been challenged for patentable subject matter or obviousness but remain enforceable in much of the US.
3.4. Subsequent Developments in DHODH Inhibitors
- Other drugs targeting DHODH (e.g., teriflunomide, brequinar) have patents filed post-2000.
- The landscape reveals a trend towards developing more selective and potent DHODH inhibitors, with claim strategies differentiating compounds by substitution patterns or specific disease indications.
4. Comparative Analysis With Other Key Patents
| Patent |
Scope |
Claim Focus |
Critical Differences |
| US 7,534,607 |
Specific DHODH inhibitors derived from the '197 patent’s class |
Structural derivatives |
More restrictive scope, focused on specific compounds |
| EP 1303453 |
Synthesis methods |
Process claims |
Validates synthesis techniques but narrower in compound scope |
| CA 2426740 |
Use of DHODH inhibitors for autoimmune diseases |
Method claims |
Therapeutic claims, potentially overlapping but narrower |
5. Implications for Industry and Innovation
- The broad coverage of compounds and therapeutic methods creates high barriers for generic entrants.
- Patent expiration lessons suggest ongoing innovation is necessary to maintain exclusivity.
- Licensing negotiations may hinge on the '197 patent’s claims, especially for biosimilar developers.
- Regulatory trends favoring combination therapies could extend patent life through method claims.
6. Deep Dive: Critical Patent Claims and Potential Infringements
| Claim Type |
Key Elements |
Potential Infringements |
Defense Strategies |
| Compound Claims |
Heterocyclic core + specific substitutions |
Generic molecules fitting the structure |
Demonstrate structural differences or non-infringement via non-overlap |
| Method of Use |
Disease indication claims |
Use of similar compounds for similar indications |
Argue different compounds or novel methods; invalidity due to obviousness |
| Formulation Claims |
Salts, polymorphs |
Use of claimed salts/formulations |
Patent expiration, or prove alternative formulations |
7. Future Outlook and Patent Strategies
- Patent Prosecution: Emphasis on claiming specific substitutions for differentiation.
- Legal Challenges: Monitor for validity challenges, especially on claim breadth.
- Innovation Directions: Focus on selective DHODH inhibitors, combination therapies, and novel indications to expand patent estate.
- Geographic Expansion: Patent filings in emerging markets to extend protections.
8. Key Takeaways
- The '197 patent's broad claims have historically provided robust protection for DHODH inhibitors, particularly early drugs like leflunomide.
- Its scope encompasses chemical compounds, methods of inhibition, and therapeutic applications, influencing subsequent patent filings.
- The patent landscape is dense, with numerous derivative patents and related claims, requiring careful navigation for companies developing DHODH-targeted therapeutics.
- Patent expiration in key markets could open opportunities for biosimilars or generics, provided other patents do not block these avenues.
- Innovators should strategize around specific chemical modifications or therapeutic methods to secure new patents that complement or succeed the '197 patent.
9. Frequently Asked Questions (FAQs)
Q1: What is the primary therapeutic use of compounds covered by U.S. Patent 6,166,197?
A: The patent broadly covers compounds used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis, transplant rejection, and certain proliferative disorders.
Q2: How does the scope of the '197 patent affect generic drug development?
A: Its broad claims create substantial barriers to entry, as generic developers must navigate potential infringement or wait for patent expiration, usually around 2020 for the key compounds.
Q3: Are there significant legal challenges to this patent?
A: While specific litigations are limited, the patent's breadth has been scrutinized. Nonetheless, it remains enforceable in the US unless invalidated through invalidity proceedings.
Q4: What is the significance of the patent claims related to specific substitutions?
A: These narrower claims provide fallback positions—if broader claims are invalidated, these specific derivatives may still be protected.
Q5: What are the main strategic considerations for companies developing DHODH inhibitors today?
A: Patent positioning, ensuring freedom to operate around key claims, developing novel compounds with unique substitution patterns, and pursuing patent filings for new therapeutic methods are critical.
References
- U.S. Patent 6,166,197. (2000). Heterocyclic inhibitors of dihydroorotate dehydrogenase.
- European Patent EP 0866300 B1.
- World Intellectual Property Organization (WIPO) Publication WO 97/36109.
- Patent landscape reports on DHODH inhibitors (e.g., from PatentScope and Espacenet databases).
- FDA and EMA approval documents for leflunomide and related drugs.
This comprehensive analysis aims to inform stakeholders—be they pharmaceutical innovators, patent counsel, or industry analysts—on the intricacies of the' 197 patent’s scope and its overarching influence in the realm of DHODH inhibitor therapeutics.
More… ↓
⤷ Start Trial
|
